BAFF inhibitor treatments, such as belimumab, have been successfully employed in the treatment of other autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis (RA) to reduce survival of autoreactive B cells. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.